Identification

Name
Ethosuximide
Accession Number
DB00593  (APRD00318)
Type
Small Molecule
Groups
Approved
Description

An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [PubChem]

Structure
Thumb
Synonyms
  • (+-)-2-Ethyl-2-methylsuccinimide
  • (±)-2-ethyl-2-methylsuccinimide
  • 2-ethyl-2-methylsuccinimide
  • 2-Methyl-2-ethylsuccinimide
  • 3-ethyl-3-methyl-2,5-pyrrolidinedione
  • 3-Ethyl-3-methylsuccinimide
  • 3-Methyl-3-ethylpyrrolidine-2,5-dione
  • 3-Methyl-3-ethylsuccinimide
  • Aethosuximide
  • alpha-Ethyl-alpha-methylsuccinimide
  • alpha-Methyl-alpha-ethylsuccinimide
  • Atysmal
  • Ethosuximid
  • Ethosuximide
  • Ethosuximidum
  • Etosuximida
  • gamma-Ethyl-gamma-methyl-succinimide
  • gamma-Methyl-gamma-ethyl-succinimide
  • Thilopemal
  • γ-ethyl-γ-methyl-succinimide
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZarontinCapsule250 mg/1OralParke Davis Div Of Pfizer Inc2000-09-22Not applicableUs
Zarontin Cap 250mgCapsule250 mgOralErfa Canada 2012 Inc1960-12-31Not applicableCanada
Zarontin Syr 250mg/5mlSyrup250 mgOralErfa Canada 2012 Inc1964-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EthosuximideSolution250 mg/5mLOralMikart, Inc.2003-12-22Not applicableUs
EthosuximideSolution250 mg/5mLOralPharmaceutical Associates, Inc.2000-11-22Not applicableUs
EthosuximideSolution250 mg/5mLOralGreenstone, Llc2002-02-27Not applicableUs
EthosuximideCapsule250 mg/1OralAvera Mc Kennan Hospital2015-10-30Not applicableUs
EthosuximideSolution250 mg/5mLOralVersa Pharm Incorporated2004-01-01Not applicableUs
EthosuximideCapsule250 1/1OralZydus Pharmaceuticals Usa, Inc.2012-10-10Not applicableUs
EthosuximideCapsule250 mg/1OralGreenstone, Llc2000-09-22Not applicableUs
EthosuximideSolution250 mg/5mLOralTeva1994-07-01Not applicableUs
EthosuximideCapsule, liquid filled250 mg/1OralBanner Life Sciences Llc.2015-06-01Not applicableUs
EthosuximideCapsule250 mg/1OralPliva, Inc.2002-11-012018-01-26Us50111 0901 01 nlmimage10 8b3245d2
International/Other Brands
Emeside (Chemidex) / Ethymal (Apotex Europe) / Etoxin (Apsen) / Petimid (Osel) / Petinimid (Gerot) / Petnidan (Desitin) / Suxilep (Jenapharm) / Suxinutin (McNeil) / Zarondan (Pfizer)
Categories
UNII
5SEH9X1D1D
CAS number
77-67-8
Weight
Average: 141.1677
Monoisotopic: 141.078978601
Chemical Formula
C7H11NO2
InChI Key
HAPOVYFOVVWLRS-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
IUPAC Name
3-ethyl-3-methylpyrrolidine-2,5-dione
SMILES
CCC1(C)CC(=O)NC1=O

Pharmacology

Indication

For the treatment of petit mal epilepsy.

Structured Indications
Pharmacodynamics

Used in the treatment of epilepsy. Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

Mechanism of action

Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.

TargetActionsOrganism
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
Absorption

Bioavailability following oral administration is 93%.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic, via CYP3A4 and CYP2E1.

Route of elimination
Not Available
Half life

53 hours

Clearance
Not Available
Toxicity

Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Ethosuximide.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Ethosuximide.Vet Approved
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethosuximide.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Ethosuximide.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethosuximide.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Ethosuximide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethosuximide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethosuximide.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Ethosuximide.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethosuximide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amperozide.Experimental
AmphetamineAmphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Ethosuximide.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Ethosuximide.Approved, Investigational
ApalutamideThe serum concentration of Ethosuximide can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethosuximide.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Ethosuximide.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Ethosuximide.Approved
ArticaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethosuximide.Approved
AtazanavirThe metabolism of Ethosuximide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ethosuximide can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Azaperone.Investigational, Vet Approved
AzelastineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ethosuximide.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Ethosuximide.Experimental
BarbexacloneThe metabolism of Ethosuximide can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benzocaine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Ethosuximide.Approved, Investigational
BenzphetamineBenzphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benzyl alcohol.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Ethosuximide.Approved, Investigational
BoceprevirThe metabolism of Ethosuximide can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Ethosuximide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ethosuximide can be decreased when it is combined with Bosentan.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Ethosuximide.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethosuximide.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Ethosuximide.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Ethosuximide.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bupivacaine.Approved, Investigational
BuprenorphineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethosuximide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethosuximide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethosuximide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Butamben.Approved, Withdrawn
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Ethosuximide.Approved
ButethalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Ethosuximide.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethosuximide.Approved, Illicit, Vet Approved
Calcium AcetateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Ethosuximide.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Canertinib.Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Ethosuximide.Experimental
CarbamazepineThe metabolism of Ethosuximide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethosuximide.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Ethosuximide.Approved, Investigational
CaseinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Ethosuximide.Approved
CeritinibThe serum concentration of Ethosuximide can be increased when it is combined with Ceritinib.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Ethosuximide.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethosuximide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethosuximide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chloroprocaine.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Ethosuximide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethosuximide.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethosuximide.Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Ethosuximide.Approved, Investigational
CimetidineThe serum concentration of Ethosuximide can be increased when it is combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.Approved
ClarithromycinThe metabolism of Ethosuximide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ethosuximide can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ethosuximide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethosuximide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ethosuximide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethosuximide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Ethosuximide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethosuximide.Approved
CobicistatThe serum concentration of Ethosuximide can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethosuximide.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ethosuximide.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Ethosuximide.Investigational
CrizotinibThe metabolism of Ethosuximide can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Ethosuximide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethosuximide.Approved
Cyproterone acetateThe serum concentration of Ethosuximide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Ethosuximide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ethosuximide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ethosuximide can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethosuximide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethosuximide.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Ethosuximide.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethosuximide.Approved, Illicit
DihydroergotamineThe metabolism of Ethosuximide can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Ethosuximide can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethosuximide.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethosuximide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Ethosuximide.Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doxepin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Ethosuximide.Approved, Investigational
DoxycyclineThe metabolism of Ethosuximide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ethosuximide is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Illicit
DronedaroneThe metabolism of Ethosuximide can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ecgonine.Experimental, Illicit
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Ethosuximide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Ethosuximide.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethosuximide.Approved, Investigational
EnzalutamideThe serum concentration of Ethosuximide can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Ethosuximide can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethosuximide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethosuximide.Approved, Investigational
EthanolEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthotoinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethosuximide.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Ethosuximide.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Ethosuximide can be decreased when combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Ethosuximide.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethosuximide.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethosuximide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethosuximide.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ethosuximide.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Ethosuximide.Experimental
FluvoxamineThe metabolism of Ethosuximide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ethosuximide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Ethosuximide.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Ethosuximide can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethosuximide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethosuximide.Approved, Illicit, Investigational
GepefrineGepefrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
GepironeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Glutethimide.Approved, Illicit
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Ethosuximide.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Ethosuximide.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Ethosuximide.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethosuximide.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Ethosuximide.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Heroin.Approved, Illicit, Investigational
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Ethosuximide.Approved, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hexobarbital.Approved
HydrocodoneEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
IdelalisibThe metabolism of Ethosuximide can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iloperidone.Approved
ImatinibThe metabolism of Ethosuximide can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethosuximide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Ethosuximide can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Ethosuximide.Withdrawn
Iofetamine I-123Iofetamine I-123 can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoleThe serum concentration of Ethosuximide can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Ethosuximide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Ethosuximide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethosuximide.Approved, Vet Approved
IsoniazidThe metabolism of Ethosuximide can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Ethosuximide can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Ethosuximide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ethosuximide can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethosuximide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Ethosuximide can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Ethosuximide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethosuximide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethosuximide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lofentanil.Illicit
LopinavirThe metabolism of Ethosuximide can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethosuximide.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethosuximide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Ethosuximide can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Ethosuximide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethosuximide.Approved
LuliconazoleThe serum concentration of Ethosuximide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ethosuximide can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Ethosuximide can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Melperone.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Ethosuximide.Experimental
MephedroneMephedrone can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MephentermineMephentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethosuximide.Approved
MethotrimeprazineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methylphenobarbital.Approved
MetyrosineEthosuximide may increase the sedative activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Ethosuximide.Experimental
MianserinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mianserin.Approved, Investigational
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Ethosuximide.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Ethosuximide.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide.Approved, Illicit
MidomafetamineMidomafetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Ethosuximide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Ethosuximide.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Investigational
MirtazapineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ethosuximide can be decreased when it is combined with Mitotane.Approved
MMDAMMDA can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Molindone.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Ethosuximide.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Ethosuximide.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Investigational
NafcillinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Ethosuximide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethosuximide.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Ethosuximide.Approved
NefazodoneThe metabolism of Ethosuximide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ethosuximide can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ethosuximide can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Ethosuximide can be increased when combined with Nevirapine.Approved
NicotineThe metabolism of Ethosuximide can be decreased when combined with Nicotine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Ethosuximide.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Ethosuximide.Investigational
NilotinibThe metabolism of Ethosuximide can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethosuximide.Approved
NitroprussideEthosuximide may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethosuximide.Approved, Vet Approved
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Ethosuximide.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethosuximide.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Ethosuximide.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethosuximide.Approved, Investigational
OlaparibThe metabolism of Ethosuximide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olopatadine.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Ethosuximide.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Ethosuximide can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ethosuximide can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethosuximide.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Ethosuximide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethosuximide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethosuximide.Approved, Investigational, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Ethosuximide.Investigational
PalbociclibThe serum concentration of Ethosuximide can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethosuximide.Approved
ParaldehydeEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Penfluridol.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Ethosuximide.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide.Approved, Vet Approved
PentobarbitalThe metabolism of Ethosuximide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethosuximide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethosuximide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Ethosuximide can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenoxyethanol.Approved
PhenterminePhentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ethosuximide.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethosuximide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Ethosuximide can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ethosuximide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleEthosuximide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Ethosuximide.Approved
PregabalinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Prilocaine.Approved
PrimidoneThe metabolism of Ethosuximide can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethosuximide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethosuximide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ethosuximide is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Ethosuximide.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethosuximide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethosuximide.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Raclopride.Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Ethosuximide.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Ethosuximide can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethosuximide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethosuximide.Approved, Investigational
RifabutinThe metabolism of Ethosuximide can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Ethosuximide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ethosuximide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Ethosuximide.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethosuximide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ritanserin.Investigational
RitobegronRitobegron can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Romifidine.Vet Approved
RopiniroleEthosuximide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ropivacaine.Approved
RotigotineEthosuximide may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Ethosuximide can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethosuximide.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Ethosuximide.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Ethosuximide.Approved, Investigational, Vet Approved
SaquinavirThe metabolism of Ethosuximide can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethosuximide.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sepranolone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Ethosuximide.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethosuximide.Approved, Vet Approved
SildenafilThe metabolism of Ethosuximide can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Ethosuximide.Approved
SiltuximabThe serum concentration of Ethosuximide can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ethosuximide can be increased when it is combined with Simeprevir.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Ethosuximide.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Ethosuximide.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
St. John's WortThe serum concentration of Ethosuximide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Ethosuximide can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Ethosuximide.Approved
SulfisoxazoleThe metabolism of Ethosuximide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sultopride.Experimental
SuvorexantEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Ethosuximide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tasimelteon.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Ethosuximide.Approved, Investigational
TelaprevirThe metabolism of Ethosuximide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ethosuximide can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethosuximide.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Ethosuximide.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Ethosuximide.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Ethosuximide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrodotoxin.Investigational
ThalidomideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethosuximide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethosuximide.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Ethosuximide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Ethosuximide can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Ethosuximide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethosuximide.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Ethosuximide.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Ethosuximide.Approved, Investigational, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethosuximide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethosuximide.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethosuximide.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethosuximide.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Ethosuximide.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Ethosuximide.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethosuximide.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Ethosuximide.Investigational
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ethosuximide.Approved, Investigational
VemurafenibThe serum concentration of Ethosuximide can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Ethosuximide can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Veralipride.Experimental
VerapamilThe metabolism of Ethosuximide can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Ethosuximide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethosuximide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ethosuximide can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zolazepam.Vet Approved
ZolpidemEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethosuximide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethosuximide.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Miller, C.A. and Long, L.M.; U.S. Patent 2,993,835; July 25,1961; assigned to Parke, Davis and Company.

General References
  1. Patsalos PN: Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:140-8. [PubMed:16302888]
  2. Coulter DA, Huguenard JR, Prince DA: Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett. 1989 Mar 13;98(1):74-8. [PubMed:2710401]
  3. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161]
  4. Coulter DA, Huguenard JR, Prince DA: Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol. 1990 Aug;100(4):800-6. [PubMed:2169941]
  5. Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN: Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons. Neuroscience. 1992 Dec;51(4):755-8. [PubMed:1336826]
External Links
Human Metabolome Database
HMDB0014731
KEGG Drug
D00539
KEGG Compound
C07505
PubChem Compound
3291
PubChem Substance
46507617
ChemSpider
3175
BindingDB
50240424
ChEBI
4887
ChEMBL
CHEMBL696
Therapeutic Targets Database
DAP000526
PharmGKB
PA449533
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ethosuximide
ATC Codes
N03AD51 — Ethosuximide, combinationsN03AD01 — Ethosuximide
AHFS Codes
  • 28:12.20 — Succinimides
FDA label
Download (174 KB)
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2TerminatedPreventionMigrainous Headache1
2CompletedSupportive CareCancers / Peripheral Neuropathy1
2CompletedTreatmentNeuropathic Traumatic Pain / Pain NRS ≥ 41
2Not Yet RecruitingTreatmentIrritable Bowel Syndrome (IBS)1
2TerminatedTreatmentComplex Regional Pain Syndromes (CRPS)1
3CompletedTreatmentChildhood Absence Epilepsy / Epilepsies / Petit Mal Epilepsy / Seizures1
4RecruitingTreatmentEpilepsies1

Pharmacoeconomics

Manufacturers
  • Banner pharmacaps inc
  • Convenant pharma inc
  • Parke davis div warner lambert co
  • Mikart inc
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Parke davis pharmaceutical research div warner lambert co
Packagers
  • Barr Pharmaceuticals
  • Catalent Pharma Solutions
  • Mikart Inc.
  • Pfizer Inc.
  • Pharmaceutical Association
  • Pliva Inc.
  • Swiss Caps Ag
  • Teva Pharmaceutical Industries Ltd.
  • Versapharm Inc.
Dosage forms
FormRouteStrength
CapsuleOral250 1/1
CapsuleOral250 mg/1
Capsule, liquid filledOral250 mg/1
SolutionOral250 mg/5mL
CapsuleOral250 mg
SyrupOral250 mg
Prices
Unit descriptionCostUnit
Ethosuximide 250 mg/5ml Solution 474ml Bottle84.2USD bottle
Ethosuximide 250 mg capsule1.26USD capsule
Zarontin 250 mg capsule1.16USD capsule
Zarontin 250 mg/5ml Solution0.34USD ml
Zarontin 50 mg/ml Syrup0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)64.5 °CPhysProp
water solubility39.2 g/LNot Available
logP0.38ATKINSON,HC & BERG,EJ (1988)
Predicted Properties
PropertyValueSource
Water Solubility101.0 mg/mLALOGPS
logP0.1ALOGPS
logP0.55ChemAxon
logS-0.15ALOGPS
pKa (Strongest Acidic)10.73ChemAxon
pKa (Strongest Basic)-6.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.17 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity35.96 m3·mol-1ChemAxon
Polarizability14.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9983
Caco-2 permeable+0.5262
P-glycoprotein substrateNon-substrate0.5832
P-glycoprotein inhibitor INon-inhibitor0.7859
P-glycoprotein inhibitor IINon-inhibitor0.9923
Renal organic cation transporterNon-inhibitor0.8867
CYP450 2C9 substrateNon-substrate0.8492
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.5108
CYP450 1A2 substrateNon-inhibitor0.9242
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9276
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.93
Ames testNon AMES toxic0.858
CarcinogenicityNon-carcinogens0.8526
BiodegradationNot ready biodegradable0.9299
Rat acute toxicity1.9213 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9939
hERG inhibition (predictor II)Non-inhibitor0.9795
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.34 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-08mi-9400000000-44583cdc88d3203a4e84
GC-MS Spectrum - CI-BGC-MSsplash10-0006-1900000000-1c27ada66f7846f9d155
GC-MS Spectrum - CI-BGC-MSsplash10-0006-2900000000-19e57defe9ded4ed42b4
Mass Spectrum (Electron Ionization)MSsplash10-08mi-9300000000-3d87944377ee1f85803d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrrolidine-2-ones. These are pyrrolidines which bear a C=O group at position 2 of the pyrrolidine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolidines
Sub Class
Pyrrolidones
Direct Parent
Pyrrolidine-2-ones
Alternative Parents
N-unsubstituted carboxylic acid imides / Dicarboximides / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
2-pyrrolidone / Carboxylic acid imide / Dicarboximide / Carboxylic acid imide, n-unsubstituted / Lactam / Carboxylic acid derivative / Azacycle / Carbonyl group / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
pyrrolidinone, dicarboximide (CHEBI:4887)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:01